Hospitals Raise Concerns on Biden Drug Shortage Proposal

HHS recently released a proposal to address drug shortages with measures focused on both hospitals and drug manufacturers.
While the Biden administration’s proposal to address drug shortages does not exempt certain drug products from 340B pricing like the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Stakeholders Clash on Patient Definition, 340B Spending Requirements in Comments on Senate ‘Group of Six’ Draft Overhaul

Advocacy groups for providers and drugmakers had diverging views in their comments on a draft Senate 340B overhaul.
Stakeholders disagreed on whether Congress should codify a new 340B patient definition or restrict how providers use 340B savings, in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

As Deadline Approaches, First Stakeholders Respond to Senate Group of Six Draft 340B Overhaul

The deadline for stakeholders to respond to the bipartisan senate "group of six" 340B draft 340B overhaul is April 1.
Less than four days remain for stakeholders to comment on the highly anticipated bipartisan senate draft 340B program overhaul, and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Influential House GOP Group Calls for Major Medicaid Cuts and 340B Revenue to ‘Go Where Intended’

The Republican Study Committee's proposed fiscal year 2025 budget includes calls for changes to the 340B program.
An influential conservative congressional caucus is urging Congress to significantly cut Medicaid spending and “ to ensure that drug discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Long-Awaited Federal Bill to Protect Contract Pharmacy Arrangements Introduced

Doris Matsui
Rep. Doris Matsui (D-Calif.) introduced federal legislation to prohibit drugmaker 340B contract pharmacy restrictions.
Long-awaited federal legislation to bar drugmaker restrictions on 340B contract pharmacy arrangements was introduced today. The Mar 12 bill sponsored [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Biden Budget Request Keeps OPA Funding Flat

President Joe Biden's fiscal year 2025 budget would increase HRSA funding but not the budget of OPA, the office that oversees the 340B program.
Despite the looming finalization of a major policy change, this week’s fiscal year 2025 budget request would freeze the budget [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Amid Double Digit 2023 Growth in 340B, NACHC Urges Federal Over State Reform

Vacheria Keys, director of regulatory affairs at NACHC, said the organization was focused on comprehensive federal 340B reform.
Unreleased figures show “double digit growth again for the 340B program” in 2023, the leader of the 340B prime vendor [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Republican Heavyweights Enter Race to Lead House Committee that Oversees 340B

Rep. Brett Guthrie (R-Ky.) will run to chair the House E&C Committee next session--and is considered by some lobbyists as the favorite to win--if Republicans maintain control of the House.
If House Republicans maintain control of the chamber after the November elections, several senior members will likely vie to chair [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

User Fees in Senate Group of Six Bill Raise Provider Concerns But Unlikely To Scuttle Bill

Bill Von Oehsen
William von Oehsen, principal at the law firm Powers, said the SUSTAIN ACT is "not going to live or die based on the user fee."
The inclusion of a provision in draft 340B reform legislation creating “user fees” on 340B covered entities (CEs) is likely [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

340B Arises Briefly in Much-Anticipated Senate Hearing on High Prescription Drug Prices

Joaquin Duato, CEO of J&J, said 340B "is an important program" in response to questioning from Sen. Roger Marshall (R-Kan.).
One influential Republican senator criticized 340B and another Republican senator expressed support for the program during today’s much-awaited Senate committee [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live